ExpressCells
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ExpressCells - overview
Established
2018
Location
Philadelphia, PA, US
Primary Industry
Biotechnology
About
Based in Philadelphia, US, and founded in 2018, ExpressCells operates as a biotechnology company that creates knock-in cell lines for biological research and uses CRISPR plus a proprietary genetic vector system to create custom cells for research. In April 2021, ExpressCells raised USD 590,500 in series A2 funding from MIT Alumni Angels of Northern California, Tech Coast Angels, and Berkeley Angel Network, with participation from Ben Franklin Technology Partners, etc. ExpressCells assists in making precise cuts into a cell's genome and then uses a patent-pending plasmid system to insert new genes into the cell to create a genetically altered cell line, allowing researchers to visualize proteins and organelles inside the cell. The company plans to use the funding to support operations expansion and increased promotion.
Current Investors
Rowan University, Keiretsu Forum Mid-Atlantic, Ben Franklin Technology Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.xpresscells.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.